Article
Alzheimer's Drug From Eisai, Biogen Gets FDA Accelerated Approval
Rating:
0.0
Views:
54
Likes:
1
Library:
1
Eisai Co. and its partner Biogen Inc. gained initial US regulatory clearance for lecanemab, the first treatment clearly shown to slow the advance of brain-wasting Alzheimer's disease.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value